Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Focal

This article was originally published in The Gray Sheet

Executive Summary

Equity investment of $5 mil. from Genzyme Surgical Products is the second of four installments to be received by Focal under an October 1999, $20 mil. commitment. In exchange, Genzyme gains exclusive North American marketing and distribution rights to Focal's FocalSeal-L lung surgery sealant. A PMA for the device is slated for review by FDA's General and Plastic Surgery Devices Advisory Panel on May 8. The funds will be used for the U.S. launch of the product and development of additional sealant product applications
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel